OCX vs. NYMX, TRIB, ICCC, AWH, BMRA, CDIO, MYMD, TKNO, ACHV, and POCI
Should you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), ImmuCell (ICCC), Aspira Women's Health (AWH), Biomerica (BMRA), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and Precision Optics (POCI). These companies are all part of the "medical" sector.
OncoCyte vs.
OncoCyte (NASDAQ:OCX) and Nymox Pharmaceutical (NASDAQ:NYMX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership.
Nymox Pharmaceutical has a net margin of 0.00% compared to OncoCyte's net margin of -787.97%. OncoCyte's return on equity of -34.08% beat Nymox Pharmaceutical's return on equity.
81.2% of OncoCyte shares are held by institutional investors. Comparatively, 0.8% of Nymox Pharmaceutical shares are held by institutional investors. 6.7% of OncoCyte shares are held by company insiders. Comparatively, 54.0% of Nymox Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
OncoCyte has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Nymox Pharmaceutical has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Nymox Pharmaceutical has lower revenue, but higher earnings than OncoCyte.
OncoCyte presently has a consensus target price of $1.11, suggesting a potential upside of 421.81%. Given OncoCyte's higher probable upside, equities analysts clearly believe OncoCyte is more favorable than Nymox Pharmaceutical.
Nymox Pharmaceutical received 149 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 51.55% of users gave Nymox Pharmaceutical an outperform vote while only 12.50% of users gave OncoCyte an outperform vote.
In the previous week, OncoCyte had 2 more articles in the media than Nymox Pharmaceutical. MarketBeat recorded 3 mentions for OncoCyte and 1 mentions for Nymox Pharmaceutical. Nymox Pharmaceutical's average media sentiment score of 1.89 beat OncoCyte's score of 0.47 indicating that Nymox Pharmaceutical is being referred to more favorably in the news media.
Summary
OncoCyte beats Nymox Pharmaceutical on 8 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OncoCyte Competitors List
Related Companies and Tools
